Ventus Therapeutics, which is developing therapies aimed at diseases of the innate immune system, closed a $140 million Series C financing round that will be used to drive three lead programs into the clinic during 2022.
MMR Vaccine Could Invigorate Innate Immune System to Fight COVID-19
Clinical Trials, Coronavirus Disease 2019 (COVID-19), Coronavirus Vaccines, Innate Immune System, Measles, Measles Mumps Rubella (MMR), MMR (Measles Mumps Rubella) Vaccines, Mumps & Rubella, R&D, Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), VaccinesAs companies scramble to develop a vaccine against the SARS-CoV-2 virus, a team of husband and wife researchers have found that the measles, mumps, rubella (MMR) vaccine can reduce the symptoms of COVID-19.